BioTelemetry(NASDAQ:BEAT) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $53.957M. Analysts estimated a revenue of $53.750M. The revenues were 0.39% above the estimates. Earnings per share were $0.23. The reported EPS was above estimates by 27.78%. Analysts had estimated an EPS of $0.18.
BioTelemetry (BEAT) made into the market gainers list on Wednesdays trading session with the shares advancing 0.81% or 0.2 points. Due to strong positive momentum, the stock ended at $24.95, which is also near the day’s high of $25.2. The stock began the session at $24.6 and the volume stood at 4,51,324 shares. The 52-week high of the shares is $25.9445 and the 52 week low is $10.96. The company has a current market capitalization of $704 M and it has 2,82,31,128 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Sep 20, 2016, Fred Broadway (SVP – Sales Marketing) sold 1,151 shares at $18.50 per share price.Also, On Sep 20, 2016, George Hrenko (SVP – Human Resources) sold 1,061 shares at $18.50 per share price.On Sep 13, 2016, Peter Ferola (General Counsel) sold 4,352 shares at $18.23 per share price, according to the Form-4 filing with the securities and exchange commission.